Comparative study of the safety and efficacy between the 1 470 nm laser resection of the prostate-selective massive and transurethral resection of the prostate in the treatment of benign prostatic hyperplasia

Abstract

Objective To compare the safety and efficacy of the two surgical approaches, 1 470 nm laser resection of the prostate-selective massive (LRP-SM) versus transurethral resection of the prostate (TURP), in the treatment of benign prostatic hyperplasia (BPH). Methods From February 2018 to February 2019, 98 cases of BPH were enrolled, 52 cases underwent LRP-SM, while 46 cases were treated by TURP. The operative time, hemoglobin, duration of postoperative bladder irrigation, indwelling catheterization time, hospital stay and the postoperative complications were recorded. The international prostate symptoms score (IPSS), quality of life (QOL), post-voiding residual urine (PVR), maximum urine flow rate (Qmax) were also compared. Results Patients in the LRP-SM group displayed shorter operative time [(42.2±16.3) min vs (58.4±18.2) min, P 0.05). 2 cases required blood transfusion in the TURP group after operation while none in the LRP-SM group. The incontinence presented in both groups (3 patients in the TURP group and 1 in the LRP-SM group), but all recovered within 1-3 months. Re-operations due to the urethral stricture and bladder neck contracture were needed in 1 case in the TURP group while none in the LRP-SM group. Etrograde ejaculation was reported in 16 cases of the TURP group and 4 cases in the LRP-SM group. Perioperative complications were fewer in the LRP-SM group (P<0.05). Conclusions LRP-SM is an excellent treatment for BPH as well as TURP. However, compared with TURP, LRP-SM has the advantages of less risk of bleeding, rapid recovery, and lower incidence of complications, and it is especially suitable for patients with advanced age, high risk and sexual function needed. Key words: BPH; TURP; 1 470 nm laser